GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vera Therapeutics Inc (NAS:VERA) » Definitions » EV-to-FCF

Vera Therapeutics (Vera Therapeutics) EV-to-FCF : -16.76 (As of May. 31, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Vera Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vera Therapeutics's Enterprise Value is $1,670.81 Mil. Vera Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-99.72 Mil. Therefore, Vera Therapeutics's EV-to-FCF for today is -16.76.

The historical rank and industry rank for Vera Therapeutics's EV-to-FCF or its related term are showing as below:

VERA' s EV-to-FCF Range Over the Past 10 Years
Min: -28.44   Med: 0   Max: 0
Current: -16.76

VERA's EV-to-FCF is ranked worse than
100% of 382 companies
in the Biotechnology industry
Industry Median: 7.97 vs VERA: -16.76

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-31), Vera Therapeutics's stock price is $37.98. Vera Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.050. Therefore, Vera Therapeutics's PE Ratio for today is At Loss.


Vera Therapeutics EV-to-FCF Historical Data

The historical data trend for Vera Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vera Therapeutics EV-to-FCF Chart

Vera Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -20.83 -6.72 -6.25

Vera Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.08 -6.69 -5.43 -6.25 -20.03

Competitive Comparison of Vera Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Vera Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vera Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vera Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Vera Therapeutics's EV-to-FCF falls into.



Vera Therapeutics EV-to-FCF Calculation

Vera Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1670.806/-99.719
=-16.76

Vera Therapeutics's current Enterprise Value is $1,670.81 Mil.
Vera Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-99.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vera Therapeutics  (NAS:VERA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Vera Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=37.98/-2.050
=At Loss

Vera Therapeutics's share price for today is $37.98.
Vera Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.050.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Vera Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Vera Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Vera Therapeutics (Vera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8000 Marina Boulevard, Suite 120, Brisbane, CA, USA, 94005
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Executives
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Marshall Fordyce director, officer: President and CEO C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Celia Lin officer: Chief Medical Officer C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Joanne Curley officer: Chief Development Officer C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Sean Grant officer: Chief Financial Officer C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Beth C Seidenberg director
Sofinnova Management X-a, L.l.c. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Longitude Capital Partners Iv, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Fund, L.p. 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Patrick G Enright director, 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Abingworth Bioventures 8 Lp 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004

Vera Therapeutics (Vera Therapeutics) Headlines

From GuruFocus

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

By Stock market mentor Stock market mentor 02-01-2023

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

By Stock market mentor Stock market mentor 02-02-2023

FMR LLC Adjusts Stake in Vera Therapeutics Inc

By GuruFocus Research 11-14-2023